WASHINGTON, Sept 13 (Reuters) - Cornerstone Therapeutics Inc failed to win a U.S. panel's support on Thursday for a drug that treats low sodium levels in the blood.
A panel of outside advisers to the Food and Drug Administration voted five to three to recommend rejection of lixivaptan for treating low sodium due to a condition that causes the body to have excess water. They also unanimously voted against using the drug to treat low sodium in heart failure patients.
The FDA usually follows panel recommendations, although it is not required to, and a final decision is expected by Oct. 29.
Shares of the company were halted pending the panel meeting. (Reporting by Anna Yukhananov; Editing by Gerald E. McCormick)